Literature DB >> 8294097

Characterization of the antiviral effects of 2' carbodeoxyguanosine in ducks chronically infected with duck hepatitis B virus.

W S Mason1, J Cullen, J Saputelli, T T Wu, C Liu, W T London, E Lustbader, P Schaffer, A P O'Connell, I Fourel.   

Abstract

This study was carried out to evaluate benefits and limitations of long-term therapy of hepatitis B virus infections with a nucleoside analog inhibitor of virus replication. The model we used was the domestic duck chronically infected with duck hepatitis B virus by in ovo infection. 2' Carbodeoxyguanosine was used as an inhibitor of viral DNA synthesis. In all animals examined there was a reduction in virus production during therapy. A dose of 2' carbodeoxyguanosine of 10 micrograms/kg every other day reduced the number of infected hepatocytes from greater than 95% to 25% to 50% in less than 3 mo, whereas a 10-fold higher dose produced a decline to less than 10%. Histological evaluation revealed mild to moderate liver injury in ducks receiving the higher dose of 2' carbodeoxyguanosine, suggesting that disappearance of infected hepatocytes may have been accelerated by a toxic effect of the drug. Drug treatment did not completely eliminate duck hepatitis B virus from any duck, and replication was restored in all hepatocytes within a few weeks to several months after antiviral therapy was terminated. Our results suggest that elimination of a chronic infection with a single inhibitor of replication may be difficult in a host that lacks an antiviral immune response capable of eliminating at least a portion of the infected hepatocytes and of ultimately producing antibodies capable of neutralizing residual virus.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8294097

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  17 in total

1.  Dynamic changes of HBV DNA in serum and peripheral blood mononuclear cells of chronic hepatitis patients after lamivudine treatment.

Authors:  Chang-Zheng Ke; Yue Chen; Zuo-Jiong Gong; Zhong-Ji Meng; Li Liu; Ze-Jiu Ren; Zuo-Hua Zhou
Journal:  World J Gastroenterol       Date:  2006-07-07       Impact factor: 5.742

2.  Inhibitory effect of adefovir on viral DNA synthesis and covalently closed circular DNA formation in duck hepatitis B virus-infected hepatocytes in vivo and in vitro.

Authors:  Julien Delmas; Olivier Schorr; Catherine Jamard; Craig Gibbs; Christian Trépo; Olivier Hantz; Fabien Zoulim
Journal:  Antimicrob Agents Chemother       Date:  2002-02       Impact factor: 5.191

3.  Evidence that hepatocyte turnover is required for rapid clearance of duck hepatitis B virus during antiviral therapy of chronically infected ducks.

Authors:  I Fourel; J M Cullen; J Saputelli; C E Aldrich; P Schaffer; D R Averett; J Pugh; W S Mason
Journal:  J Virol       Date:  1994-12       Impact factor: 5.103

4.  Inhibition of duck hepatitis B virus replication by 2',3'-dideoxy-3'-fluoroguanosine in vitro and in vivo.

Authors:  P Hafkemeyer; A Keppler-Hafkemeyer; M A al Haya; M von Janta-Lipinski; E Matthes; C Lehmann; W B Offensperger; S Offensperger; W Gerok; H E Blum
Journal:  Antimicrob Agents Chemother       Date:  1996-03       Impact factor: 5.191

Review 5.  Targeting hepatitis B therapy to the liver. Clinical pharmacokinetic considerations.

Authors:  P C Rensen; R L de Vrueh; T J van Berkel
Journal:  Clin Pharmacokinet       Date:  1996-08       Impact factor: 6.447

6.  Long-term therapy with the guanine nucleoside analog penciclovir controls chronic duck hepatitis B virus infection in vivo.

Authors:  E Lin; C Luscombe; D Colledge; Y Y Wang; S Locarnini
Journal:  Antimicrob Agents Chemother       Date:  1998-08       Impact factor: 5.191

7.  The guanine nucleoside analog penciclovir is active against chronic duck hepatitis B virus infection in vivo.

Authors:  E Lin; C Luscombe; Y Y Wang; T Shaw; S Locarnini
Journal:  Antimicrob Agents Chemother       Date:  1996-02       Impact factor: 5.191

8.  2',3'-dideoxy-beta-L-5-fluorocytidine inhibits duck hepatitis B virus reverse transcription and suppresses viral DNA synthesis in hepatocytes, both in vitro and in vivo.

Authors:  F Zoulim; E Dannaoui; C Borel; O Hantz; T S Lin; S H Liu; C Trépo; Y C Cheng
Journal:  Antimicrob Agents Chemother       Date:  1996-02       Impact factor: 5.191

9.  Entecavir therapy combined with DNA vaccination for persistent duck hepatitis B virus infection.

Authors:  Wendy K Foster; Darren S Miller; Patricia L Marion; Richard J Colonno; Ieva Kotlarski; Allison R Jilbert
Journal:  Antimicrob Agents Chemother       Date:  2003-08       Impact factor: 5.191

10.  Effects of pyrimidine and purine analog combinations in the duck hepatitis B virus infection model.

Authors:  Béatrice Seignères; Perrine Martin; Bettina Werle; Olivier Schorr; Catherine Jamard; Laurence Rimsky; Christian Trépo; Fabien Zoulim
Journal:  Antimicrob Agents Chemother       Date:  2003-06       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.